- Home
- CATX vs RNAC Comparison
CATX vs RNAC Comparison
Compare CATX & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- RNAC
- Stock Information
- Founded
- CATX 1983
- RNAC 2007
- Country
- CATX United States
- RNAC United States
- Employees
- CATX N/A
- RNAC N/A
- Industry
- CATX Medical/Dental Instruments
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- RNAC Health Care
- Exchange
- CATX Nasdaq
- RNAC Nasdaq
- Market Cap
- CATX 239.0M
- RNAC 276.3M
- IPO Year
- CATX N/A
- RNAC 2016
- Fundamental
- Price
- CATX $3.87
- RNAC $10.33
- Analyst Decision
- CATX Strong Buy
- RNAC Strong Buy
- Analyst Count
- CATX 10
- RNAC 4
- Target Price
- CATX $12.90
- RNAC $40.00
- AVG Volume (30 Days)
- CATX 835.6K
- RNAC 84.4K
- Earning Date
- CATX 11-11-2025
- RNAC 11-06-2025
- Dividend Yield
- CATX N/A
- RNAC N/A
- EPS Growth
- CATX N/A
- RNAC N/A
- EPS
- CATX N/A
- RNAC N/A
- Revenue
- CATX $1,235,000.00
- RNAC $1,026,000.00
- Revenue This Year
- CATX N/A
- RNAC N/A
- Revenue Next Year
- CATX N/A
- RNAC N/A
- P/E Ratio
- CATX N/A
- RNAC N/A
- Revenue Growth
- CATX N/A
- RNAC N/A
- 52 Week Low
- CATX $1.60
- RNAC $8.46
- 52 Week High
- CATX $13.44
- RNAC $26.50
- Technical
- Relative Strength Index (RSI)
- CATX 53.74
- RNAC 48.26
- Support Level
- CATX $3.37
- RNAC $9.39
- Resistance Level
- CATX $3.78
- RNAC $10.48
- Average True Range (ATR)
- CATX 0.20
- RNAC 0.54
- MACD
- CATX 0.04
- RNAC 0.07
- Stochastic Oscillator
- CATX 66.14
- RNAC 64.09
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.